Mannitol Viaflo Baxter (Mannitol)

Mannitol remains largely in the extracellular space, creating an osmotic gradient that draws water into the renal tubules and from edematous tissues such as the brain and eye. This fluid shift increases urine output and reduces pressure in the skull and eye.

The dose of Mannitol is individualized by the prescribing clinician based on the patient’s condition, weight, renal function, and therapeutic goal. Healthcare professionals determine the infusion rate and total amount required for each specific indication.

Mannitol’s pregnancy category is unknown, and there is limited data on its use during lactation. It should only be administered to pregnant or nursing patients when the potential benefit outweighs any possible risk to the fetus or infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where applicable) and necessary import documentation.

Unlike loop or thiazide diuretics that act on specific nephron segments, Mannitol works by osmotic forces, producing rapid fluid removal without direct tubular ion transport inhibition. This makes it especially useful for urgent reduction of intracranial or intraocular pressure, whereas other diuretics are primarily employed for chronic fluid management.

Mannitol intravenous solution should be stored at 2‑8 °C, kept refrigerated, protected from light, and never frozen or shaken. Before use, inspect the container for particulate matter and ensure the solution is at room temperature if required for infusion.

Mannitol is given by intravenous infusion. The healthcare professional selects an appropriate infusion rate, monitors vital signs and urine output, and may adjust the speed based on the patient’s response and tolerance.

Serious risks include pulmonary edema from fluid overload, acute renal failure especially in patients with pre‑existing kidney disease, severe electrolyte disturbances such as hypernatremia, and rare hemolysis. Prompt recognition and monitoring are essential to mitigate these complications.

Mannitol is contraindicated in patients with established anuria, severe renal impairment, active pulmonary edema, uncontrolled electrolyte imbalances, or known hypersensitivity to the product. Caution is also advised in individuals with severe heart failure or intracerebral hemorrhage where rapid fluid shifts may be harmful.